Severin Schwan (AP Images)
July 22, 2021 07:03 AM EDT
FDA+

Roche CEO Schwan puts 3-time Alzheimer's los­er gan­tenerum­ab back in the spot­light as FDA's con­tro­ver­sial Aduhelm OK in­spires block­buster fore­casts

John Carroll

Editor & Founder

Four years af­ter Roche opt­ed to res­ur­rect its late-stage ef­fort on their Alzheimer’s pro­gram for gan­tenerum­ab fol­low­ing a clear fail­ure, Roche CEO Sev­erin Schwan is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times